Compare PGEN & MIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGEN | MIAX |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2013 | 2025 |
| Metric | PGEN | MIAX |
|---|---|---|
| Price | $6.39 | $35.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $13.65 | ★ $47.40 |
| AVG Volume (30 Days) | ★ 4.6M | 1.7M |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.03 | ★ 1.95 |
| Revenue | $230,981,000.00 | ★ $1,364,073,000.00 |
| Revenue This Year | $2,365.68 | N/A |
| Revenue Next Year | $85.75 | $9.82 |
| P/E Ratio | $220.17 | ★ $17.17 |
| Revenue Growth | N/A | ★ 19.65 |
| 52 Week Low | $3.04 | $29.06 |
| 52 Week High | $8.98 | $57.14 |
| Indicator | PGEN | MIAX |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 54.67 |
| Support Level | $6.08 | $29.06 |
| Resistance Level | $7.44 | $44.33 |
| Average True Range (ATR) | 0.44 | 1.50 |
| MACD | -0.17 | 0.73 |
| Stochastic Oscillator | 2.37 | 95.89 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Miami International Holdings Inc is engaged in operating regulated financial marketplaces across multiple asset classes using proprietary technology platforms. The company operates exchange markets for options, equities, futures, and international listings through its MIAX Exchanges, MIAX Futures Exchange, and the Bermuda Stock Exchange. The company operates through four reportable segments: Options, which provides trading and market data services for listed equity and ETP options; Equities, which provides trading services for U.S. equities and ETPs; Futures, which provides futures trading and clearing services through MIAX Futures; and International, which provides listing services for capital market instruments through the Bermuda Stock Exchange and The International Stock Exchange.